SCHEMBL7147155

SCHEMBL7147155

COC(=O)Cc1cc2ccc(OC)cc2nc1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.68
KDM4E B2RXH2 8/20 0.68
GFER P55789 1/20 0.66
L3MBTL1 Q9Y468 3/20 0.52
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
MAPT P10636 3/20 0.51
NFKB1 P19838 2/20 0.51
NFKB2 Q00653 2/20 0.51
RELA Q04206 2/20 0.51
HSD17B10 Q99714 2/20 0.51
TP53 P04637 1/20 0.51
CLK1 P49759 1/20 0.51
KMT2A Q03164 3/20 0.50
NPSR1 Q6W5P4 2/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16047420 0.88 ALDH1A1 (0.64) ALDH1A1KDM4EGFERL3MBTL1NPC1
SCHEMBL7076958 0.87 ALDH1A1 (0.65) ALDH1A1KDM4EGFERL3MBTL1NPC1
SCHEMBL25947756 0.81 ALDH1A1 (1.00) ALDH1A1KDM4EGFERL3MBTL1NPC1
SCHEMBL27581989 0.78 KDM4E (0.64) ALDH1A1KDM4EGFERL3MBTL1NPC1
SCHEMBL7076605 0.78 ALDH1A1 (0.53) ALDH1A1KDM4EGFERL3MBTL1NPC1
SCHEMBL14065435 0.77 ALDH1A1 (0.78) ALDH1A1KDM4EGFERL3MBTL1NPC1
SCHEMBL24373427 0.76 KDM4E (0.57) ALDH1A1KDM4EGFERL3MBTL1NPC1
SCHEMBL27581986 0.76 KDM4E (0.61) ALDH1A1KDM4EGFERL3MBTL1NPC1
SCHEMBL23151910 0.76 GRM1 (0.42) ALDH1A1KDM4EL3MBTL1RAB9AMAPT
SCHEMBL473984 0.75 ALDH1A1 (0.53) ALDH1A1KDM4EL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514991-B2 Treating metabolic disorders mediated by insulin resistance or hyperglycemia; treating or inhibiting type 11 diabetes or urinary incontinence; increasing the lean meat to fat ratio in a mammal WYETH 2003-02-04 US disclosed
US-20020068751-A1 Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068751-A1 Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 ALDH1A1 876/4885KDM4E 4227/4885GFER 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.